DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

RTTNews | 799 dagar sedan
DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

(RTTNews) - Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Wednesday that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS).

The company said preparations are underway to resume the ReMEDy2 trial as soon as possible.

The ReMEDy2 trial is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Company's product candidate, DM199, to treat acute ischemic stroke (AIS) patients.

The trial is intended to enroll approximately 350 patients at 75 sites in the United States. Patients enrolled in the trial will be treated for three weeks with either DM199 or placebo, beginning within 24 hours of the onset of AIS symptoms, with the final follow-up at 90 days.

For More Such Health News, visit rttnews.com

read more
DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer

DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer

Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Monday the appointment of Lorianne Masuoka as Chief Medical Officer. Masuoka is a board-certified neurologist with more than 25 years of experience in managing clinical programs from early stage to drug approvals and strategic alliances.
RTTNews | 584 dagar sedan
Swiss Market Ends Marginally Up

Swiss Market Ends Marginally Up

The Switzerland market ended marginally up on Thursday after a choppy ride as stocks swung between gains and losses right through the day's trading session.
RTTNews | 3h 14minuter sedan
European Stocks Close Weak

European Stocks Close Weak

European stocks closed lower on Thursday as the mood remained largely cautious with investors closely following geopolitical news, digesting tech giant Nvidia's earnings, and some crucial economic data from the U.S.
RTTNews | 3h 33minuter sedan
U.S. Pending Home Sales Fall More Than Expected In July

U.S. Pending Home Sales Fall More Than Expected In July

A report released by the National Association of Realtors on Thursday showed pending home sales in the U.S. fell by more than expected in the month of July. NAR said its pending home sales index decreased by 0.4 percent to 71.7 in July after sliding by 0.8 percent to 72.0 in June. Economists had expected pending home sales to edge down by 0.1 percent.
RTTNews | 6h 34minuter sedan
Eurozone Economic Confidence Weakens In August

Eurozone Economic Confidence Weakens In August

Eurozone economic sentiment softened unexpectedly in August as only industry and retail trade showed improvements, survey results from the European Commission showed Thursday. The economic sentiment indicator slid to 95.2 in August from a revised 95.7 in the previous month. The score was forecast rise to 96.0.
RTTNews | 6h 44minuter sedan
U.S. Economy Surges More Than Previously Estimated In Q2

U.S. Economy Surges More Than Previously Estimated In Q2

The U.S. economy grew by more than previously estimated in the second quarter of 2025, according to revised data released by the Commerce Department on Thursday. The report said real gross domestic product shot up by 3.3 percent in the second quarter compared to the previously reported 3.0 percent surge. Economists had expected the jump in GDP to be upwardly revised to 3.1 percent.
RTTNews | 7h 7minuter sedan